U.S. high court considers generic-drug liability case

03/20/2013 | Reuters · Wall Street Journal, The

The Supreme Court heard arguments on Tuesday in a case involving Mutual Pharmaceutical, considering whether generic-drug makers can be held liable under state law for alleged flaws in the designs of drugs. Justices questioned if the federal Food, Drug, and Cosmetic Act, the federal mandate that requires generics to have the same design as the brand-name version, inhibits plaintiffs from making such claims under state law. Federal law surpasses state law claims as the drug has already obtained approval from the FDA, Mutual argued. A decision is anticipated by the end of June.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA